Stronger IP under EU deal will cost Canada Can$3 billion, says generics-backed report
This article was originally published in Scrip
Executive Summary
The Canadian Generic Pharmaceutical Association (CGPA) is upping the ante in its battle against the introduction of stronger intellectual property (IP) provisions in a free trade agreement that Canada is negotiating with the EU, which would adversely affect its members, but benefit the R&D pharma industry.